RSV D486N-mut. fusion protein inh.
oral antiviral clinical candidate
from lower barrier to atropisomerism of lead
Bioorg. Med. Chem., Oct. 31, 2020
Taisho Pharmaceutical, Saitama, JP
“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)